How Will The Peptide Based Metabolic Disorders Therapeutics Market Expand At A CAGR Of 13.8% Through 2029?
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Big Is The Peptide Based Metabolic Disorders Therapeutics Market Today And What Is Its Future Size?
In recent times, there has been a significant growth in the market size of peptide-based metabolic disorders therapeutics. This market is predicted to expand from $29.89 billion in 2024 to $34.1 billion in 2025 with a compound annual growth rate (CAGR) of 14.1%. Factors such as a rise in metabolic disorders, advancements in peptide synthesis methods, an increase in health care spending, an aging population, expansion in the biopharmaceutical sector, approval of new treatments from regulatory bodies, and heightened awareness of personalized medicine have all contributed to this growth in the past.
In the coming years, the market for peptide-based metabolic disorders therapeutics is anticipated to undergo fast-paced expansion, reaching $57.13 billion in 2029 with a compound annual growth rate of 13.8%. Factors contributing to the growth in the forecast period include the production of innovative peptide analogs, increased R&D investments into metabolic disorders, the application of precision medicine techniques, the broader reach into growing markets, and cooperation in drug research and development. Also, advancements in delivery technologies, with a focus on patient-oriented therapies, play a part. Key trends during the forecast period will see artificial intelligence being applied to drug discovery, personalized therapies gaining popularity, and the use of CRISPR/Cas9 for genetic treatment. Integration of wearable devices for monitoring patients, along with developments of oral peptide formulas, are emerging trends. Additionally, disease management is seeing an increase in digital therapeutics and the use of biobanking for personalized treatment is expanding.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp
Which Demand Drivers Are Strengthening The Peptide Based Metabolic Disorders Therapeutics Market?
The escalating incidence of obesity is set to fuel the expansion of the peptide-based metabolic disorders therapeutic market in the future. Obesity, defined by an excessive accumulation of body fat that poses a health threat, is on the rise due to factors such as sedentary lifestyles, poor eating habits, genetic factors and environmental influences that encourage high-calorie diets and lack of physical activity. Peptide-based metabolic disorders therapeutics are used to manage diseases like obesity by utilizing peptides to regulate metabolic functions, improve insulin sensitivity, and curb appetite, which in turn boosts patient health results and lowers ongoing health threats linked to these chronic illnesses. For example, in April 2024, The British Diabetic Association, a UK healthcare professional and research charity, reported that 4.4 million people in the UK are living with diabetes, with an additional estimated 1.2 million who may have undiagnosed type 2 diabetes. The registration statistics for 2022-23 indicate an increase of 167,822 from 2021-22. Hence, the growing prevalence of obesity is propelling the peptide-based metabolic disorder therapeutics market.
What Are The Primary Segmentation Parameters In The Peptide Based Metabolic Disorders Therapeutics Market?
The peptide based metabolic disorders therapeutics market covered in this report is segmented –
1) By Drug Type: Liraglutide, Exenatide, Other Drug Type
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity
2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide
3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders
Which Emerging Trends Are Reshaping The Peptide Based Metabolic Disorders Therapeutics Market Landscape?
Leading firms in the peptide-based metabolic disorder therapeutics market are pioneering novel peptide-based therapies, including anti-diabetic biosimilars, to fulfil unfulfilled medical requirements and broaden patient treatment choices. The term peptide-based anti-diabetic biosimilars refers to medicinal drugs that emulate existing peptide-based diabetes therapies. These biosimilars offer equivalent safety and efficiency to established treatments, and they may lower the cost of therapy through competitive pricing. For instance, Glenmark Pharmaceuticals Ltd., a pharmaceutical enterprise based in India, introduced a biosimilar named Lirafit in January 2024. This anti-diabetic drug is a biosimilar form of the well-known Liraglutide. Lirafit is part of the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class, which mirrors the function of the natural GLP-1 hormone, crucial for regulating blood sugar. This biosimilar has shown its potency in clinical trials by reducing glycemic parameters, aiding weight loss, and improving cardiovascular safety. These are essential advantages in managing diabetes and associated conditions such as obesity and cardiovascular diseases.
Who Are The Dominant Players In The Peptide Based Metabolic Disorders Therapeutics Market Today?
Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group
Access The Complete Report Here:
What Are The Emerging Regional Trends Driving The Peptide Based Metabolic Disorders Therapeutics Market?
North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=16764&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
